Search results for "Catastrophic antiphospholipid syndrome"

showing 2 items of 2 documents

Pathogenic lipid‐binding antiphospholipid antibodies are associated with severity of COVID‐19

2021

Abstract Background Coronavirus disease 19 (COVID‐19)–associated coagulopathy is a hallmark of disease severity and poor prognosis. The key manifestations of this prothrombotic syndrome—microvascular thrombosis, stroke, and venous and pulmonary clots—are also observed in severe and catastrophic antiphospholipid syndrome. Antiphospholipid antibodies (aPL) are detectable in COVID‐19 patients, but their association with the clinical course of COVID‐19 remains unproven. Objectives To analyze the presence and relevance of lipid‐binding aPL in hospitalized COVID‐19 patients. Methods Two cohorts of 53 and 121 patients from a single center hospitalized for PCR‐proven severe acute respiratory syndro…

VASCULAR BIOLOGYInflammationCatastrophic antiphospholipid syndromeblood coagulation disorderendothelial protein C receptorMiceCOVID‐19immune system diseasesAntiphospholipid syndromeCoagulopathyAnimalsHumansMedicineneoplasmsEndothelial protein C receptorbiologySARS-CoV-2business.industryantiphospholipid antibodiesCOVID-19Endothelial CellsOriginal ArticlesHematologyAntiphospholipid Syndromemedicine.diseaseThrombosisinflammationImmunologyAntibodies Antiphospholipidbiology.proteinOriginal ArticleAntibodymedicine.symptomBlood coagulation disorderbusinessJournal of Thrombosis and Haemostasis
researchProduct

THU0582 Prognostic Factors of Macrophage Activation Syndrome in Adults: Analysis of 40 Cases in 2 Tertiary Referral Centers

2016

Background Macrophage activation syndrome (MAS) is a rare, life-threatening disease in which early diagnosis and aggressive therapeutic strategy may improve the outcome [1]. Due to its rarity, epidemiologic data are still lacking. Hyperferritinemia is frequently associated with MAS and might modulate the cytokines storm the latter contributing to the development of multi-organ failure [2]. Objectives In the current study, we aimed to investigate clinical data, treatments, and outcome of adult MAS patients secondary to autoimmune rheumatic disease. Methods We retrospectively investigated clinical data, treatments, and outcome of 40 adult MAS patients secondary to autoimmune rheumatic disease…

medicine.medical_specialtyImmunologyCatastrophic antiphospholipid syndromeGastroenterologyGeneral Biochemistry Genetics and Molecular Biologychemistry.chemical_compoundTocilizumabRheumatologyInternal medicinemedicineImmunology and AllergyMacrophage activation syndrome adult onset Still‟s disease hyperferritinemic syndromebusiness.industrySeptic shockProportional hazards modelMortality ratehyperferritinemic syndromeadult onset Still‟s diseasemedicine.diseaseComorbiditySurgeryMethylprednisolonechemistryMacrophage activation syndromeMacrophage activation syndromebusinessmedicine.drugAnnals of the Rheumatic Diseases
researchProduct